Structural heart disease firm Micro Interventional Devices Inc. hopes to gain a CE mark and launch its clinical stage Permaseal transmyocardial access and closure device in Europe by the second half of 2013, with a focus on use for big-ticket transapical transcatheter aortic valve replacement procedures.
Permaseal, which the company calls the first transapical access device to enable true self-sealing, sutureless cardiac access and closure, is...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?